No Data
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $6
Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (MTD) and Neumora Therapeutics, Inc. (NMRA)
Stifel Maintains Neumora Therapeutics(NMRA.US) With Hold Rating, Maintains Target Price $3
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Biomea Fusion (BMEA) and Adaptive Biotechnologies (ADPT)
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7